From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 – January 2012

Caini, Saverio; Beck, Nam Seon; Yacouba, Harouna; Maiga, Idrissa; Chaibou, Ibrahim; Hinsa, Ide; Adakal, Aboubacar; Issoufou, Aboubacar; Kim, Sung Hye; Pezzoli, Lorenzo

doi:10.1016/j.vaccine.2013.01.015

Cited by 17 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Determinants of hesitancy in mass campaigns vary and include convenience, confidence and complacency factors, as also seen with routine programmes [62]. While neither the systematic review of strategies [63] nor the reviews examined in this article have focused on interventional research in the context of mass campaigns, the Working Group did note that successful mass campaigns had a number of common features; these include the polio elimination campaign in India [64] (although the reaction to the mass polio campaign approach has also provoked distrust in some countries), [65] polio virus containment in Israel in 2013, [66] meningococcal A campaigns in several countries in the African meningitis belt [67,68] and meningococcal C outbreak control campaigns in high-income countries, [69]. In each case, the vaccine-preventable disease was well known and feared.…”

Section: Discussionmentioning

confidence: 99%

Strategies intended to address vaccine hesitancy: Review of published reviews

Dubé

Gagnon

MacDonald

2015

Vaccine

490

377

View full text Add to dashboard Cite

When faced with vaccine hesitancy, public health authorities are looking for effective strategies to address this issue. In this paper, the findings of 15 published literature reviews or meta-analysis that have examined the effectiveness of different interventions to reduce vaccine hesitancy and/or to enhance vaccine acceptance are presented and discussed. From the literature, there is no strong evidence to recommend any specific intervention to address vaccine hesitancy/refusal. The reviewed studies included interventions with diverse content and approaches that were implemented in different settings and targeted various populations. Few interventions were directly targeted to vaccine hesitant individuals. Given the paucity of information on effective strategies to address vaccine hesitancy, when interventions are implemented, planning a rigorous evaluation of their impact on vaccine hesitancy/vaccine acceptance will be essential.

show abstract

Section: Discussionmentioning

confidence: 99%

Strategies intended to address vaccine hesitancy: Review of published reviews

Dubé

Gagnon

MacDonald

2015

Vaccine

490

377

View full text Add to dashboard Cite

show abstract

“…This could aid the development of an early warning system at the beginning of the meningitis season, following other recent attempts [47]. Despite new hope brought by the introduction of a meningococcal A conjugate vaccine [48], the ways in which the meningococcus will adapt to this changing situation are unknown and other serogroups such as W and X might replace A as the dominant serogroup. Such modelling could thus be tested on these serogroups, which would likely be influenced by most of the identified risk factors due to similar ways of transmission and invasion, and applied in other sub-Saharan countries sharing these peculiar epidemiological and climatic features.…”

Section: Discussionmentioning

confidence: 99%

Spatio-Temporal Factors Associated with Meningococcal Meningitis Annual Incidence at the Health Centre Level in Niger, 2004–2010

et al. 2014

View full text Add to dashboard Cite

BackgroundEpidemics of meningococcal meningitis (MM) recurrently strike the African Meningitis Belt. This study aimed at investigating factors, still poorly understood, that influence annual incidence of MM serogroup A, the main etiologic agent over 2004–2010, at a fine spatial scale in Niger.Methodology/Principal FindingsTo take into account data dependencies over space and time and control for unobserved confounding factors, we developed an explanatory Bayesian hierarchical model over 2004–2010 at the health centre catchment area (HCCA) level. The multivariate model revealed that both climatic and non-climatic factors were important for explaining spatio-temporal variations in incidence: mean relative humidity during November–June over the study region (posterior mean Incidence Rate Ratio (IRR) = 0.656, 95% Credible Interval (CI) 0.405–0.949) and occurrence of early rains in March in a HCCA (IRR = 0.353, 95% CI 0.239–0.502) were protective factors; a higher risk was associated with the percentage of neighbouring HCCAs having at least one MM A case during the same year (IRR = 2.365, 95% CI 2.078–2.695), the presence of a road crossing the HCCA (IRR = 1.743, 95% CI 1.173–2.474) and the occurrence of cases before 31 December in a HCCA (IRR = 6.801, 95% CI 4.004–10.910). At the study region level, higher annual incidence correlated with greater geographic spread and, to a lesser extent, with higher intensity of localized outbreaks.ConclusionsBased on these findings, we hypothesize that spatio-temporal variability of MM A incidence between years and HCCAs result from variations in the intensity or duration of the dry season climatic effects on disease risk, and is further impacted by factors of spatial contacts, representing facilitated pathogen transmission. Additional unexplained factors may contribute to the observed incidence patterns and should be further investigated.

show abstract

“…In Niger, vaccination coverage among 15-29 year olds was 66% among males and 84% among females, while coverage in 1-14 year olds was 93 and 95% among males and females, respectively [70]. Residing in the same household for more than 3 months, and being informed about the vaccination campaign were factors positively associated with being vaccinated, while the main reason for nonvaccination was not being at home during the campaign [70]. In Burkina Faso, vaccine uptake was slightly higher in households with 7-10 persons compared to households with 1-6 persons (odds ratio [OR] 1.62, 95% CI 1.21-2.16), smoking was negatively associated with vaccination among participants >15 years (OR 0.43, 95% CI 0.23-0.81), and attending private schools was associated with lower vaccine uptake than attending public schools (OR 0.13, 95% CI 0.07-0.27) [68].…”

Section: Vaccination Coveragementioning

confidence: 94%

Section: Vaccination Coveragementioning

confidence: 99%

Serogroup A meningococcal conjugate vaccines in Africa

Kristiansen

Jørgensen

Caugant

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

Serogroup A meningococcal epidemics have been a recurrent public health problem, especially in resource-poor countries of Africa. Recently, the administration in mass vaccination campaigns of a single dose of the monovalent meningococcal conjugate vaccine, MenAfriVac, to the 1-29 year-old population of sub-Saharan Africa has prevented epidemics of meningitis caused by serogroup A Neisseria meningitidis. This strategy has also been shown to provide herd protection of the non-vaccinated population. Development of meningococcal conjugate vaccines covering other serogroups and enhanced use of the pneumococcal and Haemophilus influenzae type b conjugate vaccines must be pursued to fully control bacterial meningitis in sub-Saharan Africa.

show abstract

From Agadez to Zinder: estimating coverage of the MenAfriVac™ conjugate vaccine against meningococcal serogroup A in Niger, September 2010 – January 2012

Cited by 17 publications

References 26 publications

Strategies intended to address vaccine hesitancy: Review of published reviews

Strategies intended to address vaccine hesitancy: Review of published reviews

Spatio-Temporal Factors Associated with Meningococcal Meningitis Annual Incidence at the Health Centre Level in Niger, 2004–2010

Serogroup A meningococcal conjugate vaccines in Africa

Contact Info

Product

Resources

About